From Daily Torture to Clear Skin: A Psoriasis Breakthrough

For years, Amber Dean endured the debilitating effects of plaque psoriasis, a chronic autoimmune condition that severely impacted her daily life. The 47-year-old described the experience as "daily torture," marked by persistent itching, painful skin plaques, and profound embarrassment. Her symptoms, which began in her early twenties, initially spread across her legs and feet, forcing her to always wear long clothing regardless of the weather.

Dean tried numerous treatments over the years, but their effectiveness was temporary, leading to a cycle of flare-ups and disappointment. This constant struggle eroded her self-confidence and led her to withdraw socially. She eventually found hope by joining a clinical trial for ICOTYDE, a novel oral peptide medication designed for moderate-to-severe plaque psoriasis.

Since starting ICOTYDE, Dean reports her skin is completely clear, a stark contrast to her previous condition. The U.S. Food and Drug Administration (FDA) approved ICOTYDE on March 18, marking a significant advancement as the first oral treatment option for this condition. Dean expressed astonishment at the drug's efficacy, stating, "My skin is my skin now," and encourages others with psoriasis to explore treatment options.

Dean now advocates for others living with psoriasis, emphasizing that the disease does not define them. She reflects on the shame she once carried, urging individuals to seek help and not let their condition dictate their lives. Her decision to join the ICOTYDE trial is considered one of the best health decisions she has ever made.